Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Hypercoagulability, a serious problem in patients with ESRD on maintenance hemodialysis, and its correction after kidney transplantation
American Journal of Kidney Diseases, Volume 42, No. 4, Year 2003
Notification
URL copied to clipboard!
Description
Background: Recurrent vascular access thrombosis (VAT) resulting in failure to continue maintenance hemodialysis (HD) therapy is not an uncommon event. The cause of VAT in these circumstances remains uncertain. We describe results of our studies to identify changes in hemostatic balance in patients on maintenance HD therapy that probably contributed to a hypercoagulable state. Methods: We studied 82 patients with end-stage renal disease on maintenance HD therapy who underwent HD for 11 to 52 months (39.3 ± 27.4 months). Forty-nine episodes of VAT occurred in 22 patients; a single episode occurred in 12 patients; and 2 or more episodes, in 10 patients. Blood coagulation studies, including assays of inhibitors and activated protein C (PC) resistance (APCR), were performed using standard techniques. Results: Investigations showed the presence of lupus anticoagulant (LA) in 5.6%, anticardiolipin antibody immunoglobulin G (IgG) in 3.9% and IgM in 5.3%, APCR in 20.5%, and deficiencies in protein S (PS), PC, and antithrombin III (ATIII) in 32.1%, 24.4%, and 19.2%, respectively. When parameters were compared between patients with and without VAT episodes, LA, PC, PS, and APCR levels were significantly abnormal in those who experienced VAT. Sixteen subjects with hypercoagulable states on HD therapy underwent renal transplantation and were evaluated 9.3 ± 4.2 months posttransplantation. Deficiencies in PC (P = 0.014), PS (P = 0.001), ATIII (P = 0.017), and APCR (P = 0.0001) were completely corrected in all subjects. Conclusion: Hypercoagulability is a risk factor for recurrent VAT in HD patients, and renal transplantation successfully corrects these abnormalities. © 2003 by the National Kidney Foundation, Inc.
Authors & Co-Authors
Nampoory, Mangalathillam Raman Narayanan
Unknown Affiliation
Das, Kshitish C.
Unknown Affiliation
Johny, Kaivilayil Varghese
Kuwait, Kuwait City
Kuwait University
Al-Hilali, N.
Unknown Affiliation
Abraham, Mini
Unknown Affiliation
Easow, Sicy
Unknown Affiliation
Saed, Tarek
Unknown Affiliation
Al-Muzeirei, Ibrahim A.
Unknown Affiliation
Sugathan, Thattaruparambil Natesan
Unknown Affiliation
Al-Mousawi, Musthafa S.A.
Unknown Affiliation
Statistics
Citations: 63
Authors: 10
Affiliations: 1
Identifiers
Doi:
10.1016/S0272-6386(03)00860-6
ISSN:
02726386
Research Areas
Health System And Policy